206 results about "Treatment efficacy" patented technology

The invention belongs to the technical field of medical image processing, and particularly relates to an esophageal cancer treatment effect and survival combined prediction method and system based on multiple modalities, and the method comprises the steps: obtaining a preoperative CT image and Hamp of an esophageal squamous cell carcinoma patient; e, the dyed digital pathological image, transcriptome data and clinical diagnosis and treatment information are preprocessed and subjected to feature extraction, and radiomics embedding representation, pathomics embedding representation and pipeline branch embedding representation are obtained respectively; the radiomics embedded representation, the pathomics embedded representation and the pipeline branch embedded representation are aligned and input into a multi-modal fusion module based on a multi-head self-attention mechanism for feature fusion, and fusion feature representation is generated; and based on the fusion feature representation, synchronously outputting a curative effect prediction result and a survival prediction result by using a multi-task output module, and evaluating model prediction performance by using a curative effect evaluation index and a survival analysis index.

An example method includes identifying an image of a tissue sample obtained from a subject. The tissue sample includes at least one cancer cell and at least one non-cancer cell. The example method further includes identifying the at least one non-cancer cell depicted in the image; generating a metric based on the at least one non-cancer cell depicted in the image; and predicting, based on the metric, whether the at least one cancer cell is susceptible to at least one treatment.

The present disclosure, in some aspects, provides one or more biomarkers (e.g., plasma biomarkers or circulating biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., plasma biomarkers or circulating biomarkers) described herein is regulated by DUX4. Methods (e.g., non-invasive methods) of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided. The present disclosure, in other aspects, provides one or more biomarkers (e.g., transcriptome biomarkers) for Facioscapulohumeral muscular dystrophy (FSHD). In some embodiments, a biomarker (e.g., transcriptome biomarkers) described herein is regulated by DUX4. Methods of using the biomarkers, e.g., for detection (e.g., early detection) and monitoring patient as well as treatment efficacy are also provided.

The invention discloses a treatment monitoring method and system for a percutaneous ear vagus nerve stimulation device, and the method comprises the steps: carrying out the multi-source treatment situation monitoring of a target user in a treatment course, obtaining the multi-source treatment situation monitoring data, and constructing a multi-mode treatment situation feature; real-time treatment situation analysis is carried out according to the multi-mode treatment situation features, and real-time treatment situation analysis information is generated; performing dynamic state classification based on the real-time treatment situation analysis information, evaluating the treatment condition of the target user in the current treatment course, and generating a treatment regulation and control scheme to perform treatment management and control on the current treatment course when an abnormal treatment condition exists; and constructing a treatment situation prediction model, obtaining the regulated and controlled multi-mode treatment situation characteristics, generating a floating regulation and control boundary in combination with the treatment situation prediction model, and dynamically correcting the diagnosis and treatment regulation and control scheme by using the floating regulation and control boundary to ensure the curative effect and treatment safety. The treatment effect can be accurately perceived; and the treatment safety is ensured.

Agentic AI, Contextual AI, and Generative AI systems and methods are provided for quantitative or qualitative patient analytics, blood work analytics, medical image analytics (x-ray, ultrasound, CT Scan, MRI and the like), brain scan analytics, present or historical genetic analytics and the like, to be used to guide, assist or even replace some of these physician functions with improved patient outcomes or with an improved understanding of the source of ailments, the analysis of treatment efficacy or treatment side-effects for individuals or populations of individuals. Genetic information is used to create individualized or population-based analysis, diagnostics, or treatment plans with even better outcomes.

Disclosed herein are methods of increasing sensitivity of a cancer cell to alternating electric fields comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor to the subject. Disclosed are methods of treating a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using an alternating electric field for a period of time, the alternating electric field having a frequency and field strength in combination with either an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and / or ERK inhibitor. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength; and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor.

The invention provides a method for key point detection and angle measurement of an anterior X-ray image of an ankle joint, and belongs to the technical field of image processing. According to the method, an anterior X-ray image of an ankle joint is collected, a standard data set is constructed, and the data set is utilized to train a key point detection network. The method comprises the following steps: firstly, carrying out standardization processing on an anterior X-ray image of an ankle joint, and training a key point detection model by utilizing an annotation data set; then, the trained model is applied to a new X-ray image, and detection results of 12 key points are obtained through prediction of the model. And finally, based on a key point detection result, combining a mathematical algorithm and an image processing technology to calculate the following angles: a tibia lateral malleolus angle, a tibia medial malleolus angle, a tibia articular surface angle, a tibia ankle acupoint angle, a tibia ankle angle, a fibular ankle angle, a talus inclination angle, a medial and lateral malleolus angle and a tibia talus angle. The method can provide an accurate diagnosis basis for clinicians, helps orthopedists to quickly evaluate the health condition of the ankle joint, remarkably improves the accuracy and efficiency of angle measurement, and reduces manual operation time and errors. The method has wide application prospects in the fields of ankle joint injury assessment, treatment effect monitoring and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for treating atopic dermatitis and application thereof. The composition comprises the following components: pseudo-ginseng extract, artemether, alpine glycoside and oleanolic acid in a mass ratio of (2-4): (2-4): (1-2): (1-2). The composition disclosed by the invention has anti-inflammatory and anti-pruritus effects and can be used for treating atopic dermatitis, eczema and other diseases. The active components of the composition are all from plant sources, the composition has good safety and atopic dermatitis treatment efficacy, the use dosage is low, the components can achieve a synergistic interaction effect, and the composition shows an excellent effect; the composition can be applied to functional skin care products (face cream, emulsion and essence) and external medicines (applying agents and ointments).

The invention discloses a method for constructing an osimertinib curative effect prediction model based on an elastic score and T790M mutation, and relates to the technical field of biological medicines, and the method is technically characterized in that the osimertinib curative effect prediction model based on the elastic score and the T790M mutation is constructed; the interaction mechanism between the radiomics characteristics and the EGFR mutation state is explored, so that a more accurate decision basis is provided for personalized clinical treatment, and the treatment effect is improved.

Described here are methods to utilize genomic and epigenomic detection platforms to provide quantitative metrics, including those representative of molecular phenotypes, in a variety of iimmuno-oncology applications, including those related to the characterization of patient responsiveness, treatment efficacy, adverse events among otheres. In various embodiments, described herein is an example of generating prognostic and t outcomes of a cfDNA-derived promoter methylation score in predicting ICI benefit.

The present invention relates to the field of medical testing. Specifically, the present invention provides a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer and its application. For the first time, the present invention systematically analyzed the content and spatial distribution map of the microenvironment components of CLDN18.2-positive gastric cancer tissue samples by integrating multiple fluorescent immunohistochemistry detection and whole-slice digital imaging quantitative analysis methods. Through multidimensional evaluation of the tumor microenvironment under the treatment background of CT041, a diagnostic model for predicting the prognosis of CAR-T cell immunotherapy for gastric cancer was established for the first time, which enables accurate screening of beneficiary populations and risk stratification before treatment, guides treatment selection, and improves treatment efficacy.

This invention discloses an automatic segmentation and scoring method and system for FDG PET-CT lesions in lymphoma, belonging to the field of medical image analysis technology. It aims to improve the segmentation accuracy of lymphoma lesions and the objectivity of the Deauville score. First, standardized uptake values ​​are calculated for FDG PET images, and lymph node morphological features are extracted from CT images based on multi-scale Hessian enhancement filtering to construct a dual-modality PET-CT image pair. Then, a dual-channel depth network is used to extract anatomical structural features and metabolic distribution features respectively. Cross-modal gating fusion is used to suppress physiological uptake interference, outputting preliminary lesion segmentation results. Next, three-dimensional connected component analysis is performed on the segmentation mask, and metabolic heterogeneity index is extracted by combining kurtosis and Haar wavelet multi-scale energy. A graph attention network is used to identify key lesions. Finally, the ratio of key lesions to standardized liver uptake values ​​is combined with the metabolic heterogeneity index to correct the Deauville score, achieving automation from lesion detection to treatment efficacy evaluation.

The invention provides a molecular probe targeting EDB-FN as well as a preparation method and application of the molecular probe. The structural formula of the molecular probe targeting EDB-FN is shown in the specification, according to the molecular probe targeting EDB-FN, the probe is based on a cyclic peptide probe with Lys-Glu side chain lactam bridge conformation fixed, the connection mode of a DOTA chelating agent is optimized, and the clinical transformation bottlenecks that an existing probe is poor in stability, low in affinity, insufficient in targeting specificity, poor in diagnosis and treatment integration compatibility and the like are solved. The probe can be used for early diagnosis and molecular imaging research of tumors, and provides a reliable basis for tumor malignancy degree evaluation and treatment effect monitoring.

This invention discloses the application of integrin αv inhibitors combined with γ-secretase inhibitors in the preparation of drugs for treating tumors. The study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors in tumor treatment exhibits a synergistic effect, not only inhibiting in situ tumor growth but also significantly suppressing tumor invasion, distant metastasis, and other malignant progression, thus helping to slow tumor progression, improve treatment efficacy, and enhance patient prognosis. Furthermore, the study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors can reduce the production of the intracellular free domain of integrin αv and inhibit the activation of the classical downstream pathway of integrin αv. The combined use of integrin αv inhibitors and γ-secretase inhibitors shows broad application prospects in tumor treatment.

The invention relates to the field of medical equipment, in particular to a high-precision temperature control system with weighing and heating functions for a body cavity hyperthermia perfusion therapy machine. The system comprises a peristaltic pump control device, a high-precision temperature measurement probe, a temperature acquisition device, a microwave cavity, a microwave power acquisition device, a microwave power output module, a weighing detection device, a control system and a computer. The peristaltic pump control device comprises a filling pump, a circulating pump and a draw-off pump and is used for controlling liquid medicine to flow; the weighing detection device is arranged below the microwave cavity and is used for detecting the weight of liquid in the medicine bag; and the microwave power acquisition device and the output module control microwave energy. According to the system, the temperature, the flow and the microwave power are accurately controlled, accurate regulation and control of body cavity hyperthermia perfusion treatment are achieved, and the treatment effect and safety are improved.

Disclosed herein are methods for increasing sensitivity of a cancer cell to alternating electric fields by administering an AKT inhibitor, a mammalian target of rapamycin (mTOR) inhibitor, a Phosphatidylinositol 3-Kinase (PI3K) inhibitor, and / or a Glycogen synthase kinase 3β (GSK3β) inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying alternating electric fields to a target site of the subject for a period of time, the alternating electric fields having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength in combination with either an mTOR inhibitor, AKT inhibitor, PI3K inhibitor, or GSK3β inhibitor and / or a composition or compound that increases cyclin D1. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to alternating electric fields for a period of time, the alternating electric fields having a frequency and field strength; and exposing the cancer cell to a PI3K inhibitor.

Disclosed herein are compositions and methods for treating cancer, specifically extensive-stage small-cell lung cancer (ES-SCLC), through the administration of a combination therapy. In some embodiments, the method comprises administering plinabulin, one or more immune checkpoint inhibitors, including but not limited to pembrolizumab, and a regimen of etoposide with a platinum-based agent (EP). The disclosed methods enhance tumor reduction, prolong progression-free survival, and improve overall treatment efficacy compared to traditional therapies.

The invention discloses a colorectal cancer treatment effect evaluation method, system and equipment based on SPP1 + TAMs. According to the application, the high heterogeneity of the TAM in the colorectal cancer and the metastatic microenvironment thereof is systematically revealed from three dimensions of spatial distribution, metabolic characteristics and functional states. On the basis, the invention provides a method for evaluating the treatment effect of the multi-kinase inhibitor and / or the anti-PD-1 therapy medicine on the colorectal cancer based on SPP1 + TAMs, a medicine screening method, a system, equipment and the like, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the colorectal cancer, and a clinician is guided to formulate an individualized treatment scheme for the patient; meanwhile, a new thought is provided for treatment of colorectal cancer.

Waveform characteristics of pulses in a pulse train configured to cause pulsed field tissue ablation may be varied in a manner that improves electromagnetic compatibility while retaining treatment efficacy. Such waveform characteristics may include pulse-to-pulse initiation intervals, inter-pulse delays, pulse on-times, pulse widths, inter-phase delays in the case of biphasic pulses, or a combination thereof. Such waveform characteristics may be varied in a random manner. Variations of waveform characteristics may be bounded by minimum, maximum, or both minimum and maximum differences between various pulses or pulse groups, or between various pulse trains or pulse train groups, for example, to help ensure sufficient stability of treatment signal waveforms while allowing sufficient variability, for example, to improve electromagnetic compatibility.

The present invention discloses a high-frequency electrotherapy protection device and method. This device can directly sample data from the treatment circuit, providing direct data support for treatment efficacy. This allows for differentiated treatment of different treatment sites, enabling precise, quantified treatment of diseased areas, ensuring both treatment effectiveness and accuracy. It also enables early prediction of treatment mishaps, providing dual protection against potential safety hazards. The device comprises a high-frequency electric field therapy unit, a treatment energy monitoring unit, and a control unit.

The invention relates to a method and device for predicting the curative effect of an image heterogeneity region fusion technology based on a graph network, and belongs to the technical field of intelligent medical treatment and medical image analysis. The method comprises the following steps: firstly, dividing a tumor and a region around the tumor in a medical image into a plurality of non-connected sub-regions as graph nodes, and generating a comprehensive feature representation fusing a local image feature and a node type embedding vector for each node; then, defining edges between nodes based on a spatial distance threshold value, and constructing a graph structure including intra-tumor, peritumor and cross-boundary connection; and finally, inputting the graph structure into a graph neural network model for training to obtain a curative effect prediction model. According to the method, the complex spatial topological relation between the tumor heterogeneity areas is explicitly modeled through the graph structure, the core problems of spatial information loss and insufficient heterogeneity modeling in the prior art are solved, and the accuracy and robustness of treatment effect prediction are remarkably improved.

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

A system and method of determining efficacy of treatment by at least one processor may include receiving, from at least one camera, images depicting motion of an animal that may be treated with a predetermined substance of interest. Said processor may extract from the images, a plurality of motion features representing motion of at least one specific body part of the animal, and apply a dimensionality reduction algorithm on the plurality of motion features, to obtain a latent vector representing the plurality of motion features in a latent space. The latent vector may include a plurality of latent features. Said processor may subsequently calculate a value of a behavioral indicator, representing a behavior of the animal, based on the latent features of the latent vector, and determine efficacy of the treatment based on the behavioral indicator value.

This invention belongs to the field of medical technology, and specifically relates to the application of serotonin 3 receptor antagonists in the preparation of antitumor drugs. This invention, through research, demonstrates for the first time that serotonin 3 receptor antagonists can inhibit the activity of tumor cells resistant to third-generation EGFR-TKIs. More importantly, serotonin 3 receptor antagonists can not only reverse HER2 S310F mutation-mediated resistance to third-generation EGFR-TKIs, but also reverse secondary resistance to third-generation EGFR-TKIs, thus enabling their use as antitumor drugs for patients resistant to third-generation EGFR-TKIs. The combined use of serotonin 3 receptor antagonists and third-generation EGFR-TKIs exhibits a significant synergistic effect in inhibiting the proliferation of lung adenocarcinoma cells, with minimal toxic side effects on liver and kidney function, providing an effective treatment strategy for clinically reversing third-generation EGFR-TKI resistance and improving the treatment efficacy of NSCLC.

The invention discloses an application of a T cell subset in improving the treatment effect of AK112. The T cell subset is XCL1 + CCL3 + CD8 + T cells. The invention relates to an application of a specific T cell subset in improving the curative effect of AK112, a T cell agonist and AK112 are combined for use, and by synergistically activating the T cell function and reversing the immunosuppression microenvironment, the single drug resistance of AK112 is effectively overcome, the continuous remission time is remarkably prolonged, the treatment response is deepened, the applicable patient group is expanded, and meanwhile, the toxicity risk is reduced. The invention further develops a full-spectrum flow cytometry kit containing 13 antibodies, 13 key markers of the T cell subgroup can be simultaneously detected by one tube, patients sensitive to evoximab treatment (i.e., high expression of the subgroup) can be efficiently screened out, and a convenient tool is provided for accurate medication.

The invention provides a traditional Chinese medicine extract with a folliculitis treatment effect, a preparation method of the traditional Chinese medicine extract and prepared bacteriostatic shampoo, and belongs to the technical field of daily necessities. The traditional Chinese medicine extract is prepared from the following raw materials in parts by mass: 5 to 20 parts of rhizoma coptidis, 5 to 20 parts of cortex phellodendri, 5 to 20 parts of radix scutellariae, 5 to 20 parts of vinegar frankincense, 5 to 20 parts of vinegar myrrh, 5 to 20 parts of radix et rhizoma rhei, 5 to 20 parts of rhizoma polygoni cuspidati, 5 to 20 parts of radix stemonae and 5 to 20 parts of herba taraxaci. By optimizing the compatibility and extraction process of a traditional Chinese medicine formula and combining the modern preparation technology, the invention aims to provide a traditional Chinese medicine hair washing therapeutic agent which is efficient in permeation, long-acting in bacteriostasis, safe, mild and strong in cleaning power, so as to overcome the defects of current chemical hair washing products in the field of folliculitis treatment.

The invention relates to medicine, and more particularly to therapy, and can be used for treating chronic recurrent infection caused by type 1 and 2 herpes simplex viruses (HSV). According to the proposed method, no sooner than 10-14 days after the subsidence of a repeat flare-up, an extract of aspen bark harvested in the autumn-winter period is administered as an interferon inducer in an amount of 3.7 ml 3 times per day after food and washed down with water at room temperature, the full course of treatment lasting 90 days. The invention provides increased therapeutic efficacy and a reduced frequency and duration of recurrent infection by inducing a high level of (alpha and gamma) interferons in HSV-1 and HSV-2 patients.

The utility model provides a pair of hemorrhoid postoperative nursing pants, which belongs to the technical field of hemorrhoid treatment and comprises a pants body and a convex patch adhered in the pants body, the convex patch comprises a sticking part and a convex fitting part, a flexible sticking sheet is arranged on the sticking part, the convex fitting part is arranged on the sticking part, the convex fitting part is a curved bulge, and a medicine patch is fitted on the surface of the convex fitting part. Due to the fact that the protruding type patch is arranged in the pants body, the medicine patch of the protruding attaching portion can be close to the hemorrhoid position of the patient and is slightly attached to the hemorrhoid position of the patient, compared with a traditional flat attaching mode, the protruding mode enables medicine to make contact with the hemorrhoid of the patient better, and the treatment effect can be improved when the hemorrhoid is treated, especially external hemorrhoid and mixed hemorrhoid. Meanwhile, hemorrhoid bleeding or exudates can be directly adsorbed by the convex patches, so that the trousers body of the patient is prevented from being polluted due to hemorrhoid bleeding, and the discomfort of the patient is reduced.

This invention belongs to the field of precision oncology diagnosis and treatment technology, specifically involving a nanomedicine delivery system with tumor microenvironment regulation capabilities, its preparation method, and its application. S1: An organic phase is prepared by dissolving ionizable lipids, helper phospholipids, cholesterol, and functionally modified lipids in a solvent at a molar ratio of 50:38.5:10:1.5. S2: Capsaicin is dissolved in the organic phase obtained in S1, and doxorubicin is dissolved in the solvent to prepare an aqueous phase. The organic and aqueous phases are rapidly mixed in a microfluidic device at a volume ratio of 3:1 to obtain a mixture. S3: The mixture obtained in S2 is placed in a dialysis bag and immersed in Tris buffer for magnetic stirring and dialysis, followed by concentration to obtain (C+D)@LNPPRT. This invention significantly enhances the precision detection of tumors, enables efficient early tumor detection and targeted chemotherapy, and improves treatment efficacy.